Copanlisib for Cancer
Trial Summary
Will I have to stop taking my current medications?
The trial requires that you stop using herbal medications at least 7 days before starting copanlisib. You also cannot be on strong inhibitors or inducers of CYP3A4 within two weeks before and during the study. If you are on anti-arrhythmic therapy, only digoxin or beta-blockers are allowed.
How is the drug Copanlisib unique in treating cancer?
Copanlisib is unique because it is an intravenous drug that targets the PI3K pathway, which is involved in cancer cell growth, and it has shown effectiveness in treating certain types of lymphoma and solid tumors. Unlike some other treatments, it specifically inhibits PI3K-α/δ, which may help overcome resistance mechanisms in cancer cells.12345
What is the purpose of this trial?
The phase II MATCH treatment trial tests how well copanlisib works to treat patients with cancer with PTEN loss. Copanlisib may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth.
Research Team
Jordi Rodon Ahnert
Principal Investigator
M.D. Anderson Cancer Center
Eligibility Criteria
This trial is for cancer patients with a specific genetic change called PTEN loss. Participants must be willing to undergo procedures like biopsies, provide biospecimens, and have radiologic exams.Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive copanlisib IV at a dose of 60 mg over 1 hour on day 18 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Follow-up
Participants are monitored for safety and effectiveness after treatment completion, with follow-up every 3 months for 2 years and then every 6 months for 1 year.
Treatment Details
Interventions
- Copanlisib
Find a Clinic Near You
Who Is Running the Clinical Trial?
National Cancer Institute (NCI)
Lead Sponsor